Elliott Sigal, M.D., Ph.D.,
executive vice president, chief scientific officer, and president, Research and Development
Elliott Sigal talks about the future of R&D at Bristol-Myers Squibb
WELCOME TO R&D
We take our company's mission seriously: to extend and enhance human life.
Since 1858, we’ve been on the leading edge of science and technology to discover and develop new medicines. We measure our success by the innovative medicines we bring to patients, offering them new treatment options and, more importantly, new hope. Since 2002, our R&D team has helped to bring to market nine products in oncology, schizophrenia, depression, HIV/AIDS, hepatitis B and rheumatoid arthritis. Two of these medicines are biologics. In the fight against serious disease, biologics are playing an increasingly prominent role.
Yet, we are not satisfied with past success. So now, we are in the midst of a transformation to become a new kind of enterprise—a next-generation BioPharma company.
Our vision to become a next-generation BioPharma leader means we will combine the best elements of a traditional pharmaceutical company and those of a leading-edge biotech company by focusing on innovation, selective integration, and continuous improvement.
Our R&D strategy is to pursue significant areas of unmet medical need by leveraging our legacy in discovering and developing high-potency small molecules as well as our growing experience and expertise in highly targeted biologics.
Building on the past, accelerating to the future. It’s all part of what being a next-generation BioPharma leader is all about.
In the Pipeline
Our pipeline is one of the most innovative in the industry. Learn more about the new medicines we are developing.
Disease Areas
We are working hard to develop innovative medicines to meet unmet medical needs in these areas:
R&D Highlights
October 27, 2008
Data Demonstrate ORENCIA® (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis
October 27, 2008
Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA® (abatacept) and Methotrexate (MTX) Achieved DAS28 (CRP)-Defined Remission Compared to MTX Alone
October 26, 2008
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients